Gene therapies for hemophilia hit the mark in clinical trials.
Publication
, Journal Article
Pickar, AK; Gersbach, CA
Published in: Nature medicine
February 2018
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nature medicine
DOI
EISSN
1546-170X
ISSN
1078-8956
Publication Date
February 2018
Volume
24
Issue
2
Start / End Page
121 / 122
Related Subject Headings
- United States Food and Drug Administration
- United States
- T-Lymphocytes
- Immunology
- Humans
- Hemophilia A
- Genetic Therapy
- Factor VIII
- Clinical Trials as Topic
- 42 Health sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Pickar, A. K., & Gersbach, C. A. (2018). Gene therapies for hemophilia hit the mark in clinical trials. Nature Medicine, 24(2), 121–122. https://doi.org/10.1038/nm.4492
Pickar, Adrian K., and Charles A. Gersbach. “Gene therapies for hemophilia hit the mark in clinical trials.” Nature Medicine 24, no. 2 (February 2018): 121–22. https://doi.org/10.1038/nm.4492.
Pickar AK, Gersbach CA. Gene therapies for hemophilia hit the mark in clinical trials. Nature medicine. 2018 Feb;24(2):121–2.
Pickar, Adrian K., and Charles A. Gersbach. “Gene therapies for hemophilia hit the mark in clinical trials.” Nature Medicine, vol. 24, no. 2, Feb. 2018, pp. 121–22. Epmc, doi:10.1038/nm.4492.
Pickar AK, Gersbach CA. Gene therapies for hemophilia hit the mark in clinical trials. Nature medicine. 2018 Feb;24(2):121–122.
Published In
Nature medicine
DOI
EISSN
1546-170X
ISSN
1078-8956
Publication Date
February 2018
Volume
24
Issue
2
Start / End Page
121 / 122
Related Subject Headings
- United States Food and Drug Administration
- United States
- T-Lymphocytes
- Immunology
- Humans
- Hemophilia A
- Genetic Therapy
- Factor VIII
- Clinical Trials as Topic
- 42 Health sciences